Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Sunday 05.04.2020 at 10:00 AM CEST
Settings

Settings

1. WO2020060923 - POLYURETHANE EXCIPIENT

Publication Number WO/2020/060923
Publication Date 26.03.2020
International Application No. PCT/US2019/051289
International Filing Date 16.09.2019
IPC
C08G 18/08 2006.01
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
18Polymeric products of isocyanates or isothiocyanates
06with compounds having active hydrogen
08Processes
C08G 18/12 2006.01
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
18Polymeric products of isocyanates or isothiocyanates
06with compounds having active hydrogen
08Processes
10Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
12using two or more compounds having active hydrogen in the first polymerisation step
C08G 18/32 2006.01
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
18Polymeric products of isocyanates or isothiocyanates
06with compounds having active hydrogen
28characterised by the compounds used containing active hydrogen
30Low-molecular-weight compounds
32Polyhydroxy compounds; Polyamines; Hydroxy amines
C08G 18/40 2006.01
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
18Polymeric products of isocyanates or isothiocyanates
06with compounds having active hydrogen
28characterised by the compounds used containing active hydrogen
40High-molecular-weight compounds
C08L 75/04 2006.01
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
75Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
04Polyurethanes
C08G 18/44 2006.01
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
18Polymeric products of isocyanates or isothiocyanates
06with compounds having active hydrogen
28characterised by the compounds used containing active hydrogen
40High-molecular-weight compounds
42Polycondensates having carboxylic or carbonic ester groups in the main chain
44Polycarbonates
Applicants
  • DSM IP ASSETS B.V. [NL/NL]; Het Overloon 1 6411 TE Heerlen, NL
Inventors
  • RIFFEY, Jacob; US
  • ZUPANCICH, John Andrew; US
  • AL-RASHID, Jennifer; US
Agents
  • BULL, Kevin; US
Priority Data
18197763.828.09.2018EP
62/732,07317.09.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) POLYURETHANE EXCIPIENT
(FR) EXCIPIENT DE POLYURÉTHANE
Abstract
(EN)
In an embodiment, a polyurethane comprises the residues of i. an aliphatic diisocyanate, ii. an aliphatic diol comprising a poly(ethylene oxide) moiety, iii. an aliphatic diol comprising a polycarbonate moiety, and iv. a chain extender, wherein the polyurethane has a melting temperature of 140 °C or less and has a weight average molecular weight of from 100,000 to 500,000 g/mol. In an embodiment, the polyurethane is substantially devoid of catalyst. In an embodiment, the polyurethane is formed by reactive extrusion. In an embodiment, a medical device comprises the polyurethane and a bioactive agent. The medical devices, methods, and polyurethanes may exhibit benefits in end-product biostability, drug release profile, health and safety, and processing speed or reproducibility.
(FR)
Dans un mode de réalisation, un polyuréthane comprend les résidus de i. un diisocyanate aliphatique, ii. un diol aliphatique comprenant un fragment de poly(oxyde d'éthylène), iii. un diol aliphatique comprenant une fraction polycarbonate, et iv. un allongeur de chaîne, le polyuréthane ayant une température de fusion inférieure ou égale à 140 °C et une masse moléculaire moyenne en poids de 100 000 à 500 000 g/mol. Dans un mode de réalisation, le polyuréthane est sensiblement dépourvu de catalyseur. Dans un mode de réalisation, le polyuréthane est formé par extrusion réactive. Dans un mode de réalisation, un dispositif médical comprend le polyuréthane et un agent bioactif. Les dispositifs médicaux, procédés et polyuréthanes peuvent présenter des avantages en matière de biostabilité de produit final, de profil de libération de médicament, de santé et de sécurité, et de vitesse de traitement ou de reproductibilité.
Latest bibliographic data on file with the International Bureau